AI assistant
Sending…
Salarius Pharmaceuticals, Inc. — Director's Dealing 2020
Mar 25, 2020
35494_dirs_2020-03-25_03ea0b5e-10b0-4e8e-ac3d-506df2a74724.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2020-03-23
Reporting Person: Lammers Paul (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-03-23 | Stock Option (right to buy) | $0.61 | A | 6000 | Acquired | 2030-03-22 | Common Stock (6000.0) | Direct |
Footnotes
F1: Options granted are fully vested on March 23, 2021.
More from Salarius Pharmaceuticals, Inc.
Proxy Solicitation & Information Statement
2026
Jun 4
Proxy Solicitation & Information Statement
2026
Jun 4
Regulatory Filings
2026
May 19
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Declaration of Voting Results & Voting Rights Announcements
2026
Feb 25
Major Shareholding Notification
2026
Feb 17
Proxy Solicitation & Information Statement
2026
Jan 9
Regulatory Filings
2026
Jan 8